Antibody-drug conjugates (ADCs) exploit the inherent selectivity of monoclonal antibodies to achieve targeted delivery of cytotoxic agents. By conjugating a potent small-molecule payload to an The post ADCs vs. AOCs: Shared Design Principles & Key Differences in Bioconjugate Engineering appeared first on PharmaSource .
Read Full ArticleThis article was originally published on pharmasource. Click the button above to read the complete article.
